
P R E S S R E L E A S E 1 July 2002

Sale of Kronans Droghandel completed

Since all the conditions for the sale of Ratos's shares in Kronans Droghandel to the Finnish company Orion have now been met, the deal is being completed as planned. The positive effect of the sale on Ratos's results for Q2 2002 is approximately SEK 55m.

An agreement was signed on 12 April to sell Kronans Droghandel to the Finnish company Orion. The purchase price amounted to approximately SEK 460m. Following the deal, Orion's stake in Kronans Droghandel will rise from 10.6% to nearly 70%.

Orion's subsidiary Oriola is Finland's second largest pharmaceutical distributor. Oriola is also the leading wholesaler in the distribution of medical products to the healthcare and laboratory sector in Finland. In Sweden, Oriola markets a full range programme of dental products. The acquisition of KD will allow Orion's operations in distribution of pharmaceuticals and healthcare and laboratory products to reach an effective size in the Nordic countries. Together, Oriola and KD will be the market leader in Finland and the second largest pharmaceutical distributor in Sweden.

For further information, please contact:
Arne Karlsson, CEO Ratos, +46 8 700 17 00

Financial calendar 2002:

Six-month report	26 August
Nine-month report	13 November

Ratos is a listed private equity company. The business concept is to maximise shareholder value over time by investing in, developing and divesting primarily unlisted companies. Ratos thus offers stock market players a unique investment opportunity. The net asset value of Ratos's investments is approximately SEK 9 billion. Ratos's holdings include Arcorus, Atle Industri, Camfil, Capona, Dahl, DataVis, DIAB, Dynal Biotech, Gadelius, Haendig, Haglöfs, Hilding Anders, HL Display, Industri Kapital, Intervect, Lindab, Martinsson, Q-Labs, Superfos, Telia Overseas and Yarrow.